Mangoceuticals Closes $500K Offering at 74% Premium to Market
MGRX has more than doubled off its 52-week low of $0.162.
Summary
Mangoceuticals closed a registered direct offering of approximately $500,000, priced at $0.75 per unit — a 74% premium to the recent closing price of $0.43. Each unit includes one common share and one warrant. The premium pricing is notable for a company with a market cap under $10 million and a going concern warning, suggesting the investor sees value beyond the current trading price. This follows the October 1 announcement of a $2.5 million strategic investment in the MangoRx IP subsidiary, of which $1.75 million has been received. The offering provides working capital at the parent level without the deep discount typical of distressed microcap financings.
At the time of this announcement, MGRX was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.16 to $2.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.